Posted on 2/27/17
Bristol-Myers: Buyout Bound?
Bristol-Myers Squibb (NYSE:BMY) has quickly become one of the hottest names in pharma after attracting two big name activist investors. To start, Barry Rosenstein's JANA Partners . . .
Posted on 2/27/17
Billionaire Carl Icahn Is Reportedly Buying Bristol-Myers Squibb Stock -- Should You?
Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a . . .
Posted on 2/27/17
Berkshire Hathaway Inc. Reveals Some Major Changes to Its Portfolio
In this segment from Market Foolery, the team reviews the latest portfolio updates from Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B) and its legendary CEO, Warren Buffett. The company . . .
Posted on 2/27/17
Warren Buffett's Advice for a Stock Market Crash in 2017
In Warren Buffett's latest letter to Berkshire Hathaway's (NYSE:BRK-A) (NYSE:BRK-B) shareholders, the Oracle of Omaha offered his long-term predictions for American stocks, as well as some . . .
Posted on 2/27/17
Warren Buffett Just Revealed the Best Investment Most People Can Make
In his annual letter to Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B) shareholders, Warren Buffett included an extensive discussion of investment fees, and how they can rob individual investors . . .
Posted on 2/26/17
Santhera Pharmaceuticals Announces Opening of U.S. Office in Burlington, MA
BURLINGTON, Mass. & LIESTAL, Switzerland--(BUSINESS WIRE)--Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development of innovative treatments for rare mitochondrial and neuromuscular diseases, announced . . .
Posted on 2/24/17
ProEx Physical Therapy Names Keith Cooper Manager of Beverly Location
ProEx, a physical therapist owned private practice specializing in orthopedics, spine and sports medicine is pleased to
Posted on 2/24/17
bluebird bio Inc Highlights a Data-Rich 2017
bluebird bio (NASDAQ:BLUE) reported fourth-quarter earnings after the closing bell on Wednesday. Without any products on the market, the quarterly pipeline update is more important than . . .
Posted on 2/24/17
Yale New Haven Health System to Partner with PhysicianOne Urgent Care
Two of Connecticut's leading healthcare organizations have announced a new partnership focused on providing high-quality urgent care services throughout Connecticut and Westchester County, New York. Yale . . .
Posted on 2/24/17
IFM Therapeutics Appoints Seven Physicians to Clinical Advisory Board
BOSTON--(BUSINESS WIRE)--IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system for the treatment of cancer and inflammatory disease, . . .
Posted on 2/23/17
Finch Therapeutics Announces Strategic Collaboration with OpenBiome
SOMERVILLE, Mass.--(BUSINESS WIRE)--Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank, today announced a collaboration to develop FIN-403, an orally administered . . .
Posted on 2/23/17
Peak Physical Therapy & Sports Performance Offers Cupping Therapy
Peak Physical Therapy & Sports Performance, a South Shore practice specializing in unique programs that provide holistic treatment in orthopedic, spine and sports medicine specialties, announces . . .
Posted on 2/23/17
Interleukin Genetics Deploys ILUSTRA Inflammation Management Program with mPulse Mobile Employees
Enhanced Benefit Can Deliver Significant Health and Economic Value by Targeting Chronic InflammationInterleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of . . .
Posted on 2/23/17
Who Could Buy Bristol-Myers Squibb?
Billionaire activist investor Carl Icahn has reportedly set his sights on Bristol-Myers Squibb(NYSE:BMY), a $90 billion-market-cap biopharma that's carving out an important leadership position in immuno-oncology. . . .
Posted on 2/23/17
3 Biotech Stocks You May Be Overlooking
With hundreds of biotech stocks on the market, who can keep up with them all? Probably no one. What happens as a result is that usually . . .
Posted on 2/23/17
Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat
Momenta Pharmaceuticals (NASDAQ:MNTA) reported fourth-quarter earnings on Tuesday, but analysts weren't discussing the numbers. Instead, most of their questions focused on the company's disclosure on Friday . . .
Posted on 2/23/17
How High Can Corbus Pharmaceuticals Stock Go?
Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus' share price has . . .
Posted on 2/22/17
Aetna Announces $3.3 Billion Accelerated Share Repurchase
HARTFORD, Conn.--(BUSINESS WIRE)--Aetna (NYSE: AET) today announced that it has entered into accelerated share repurchase agreements with two dealers to repurchase an aggregate of $3.3 billion . . .
Posted on 2/22/17
Did Biogen Inc. Shoot Itself in the Foot?
How would you feel about shelling out $750,000 for a year of treatment for a life-threatening disease?Well, you're not alone.Spinraza, the second drug to earn FDA . . .
Posted on 2/22/17
ImmunoGen, Inc.: Waiting to Move FORWARD
ImmunoGen (NASDAQ:IMGN) reported earnings on Friday for the quarter that ended in December. The company is switching from a fiscal year that ends in June to . . .
Posted on 2/22/17
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) and EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG), a specialty pharmaceutical company that focuses on developing and commercializing products . . .
Posted on 2/22/17
Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it
Posted on 2/22/17
FORMA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research
WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, announced today it has been awarded a research grant from The Michael J. . . .
Posted on 2/21/17
Arch Therapeutics $6.1 Million Registered Direct Offering
Arch Therapeutics, Inc. (OTCQB: ARTH), a developer of innovative materials as hemostatic and wound care devices, today announced the pricing of a registered direct offering of . . .
Posted on 2/21/17
Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.
Late last year, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) took a big hit when the company scuttled an important development program because of safety concerns. Meanwhile, plenty of . . .
Boston
